BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 216 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q3 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $8,667,000 | +14.6% | 73,100 | +33.2% | 0.01% | +25.0% |
| Q4 2021 | $7,562,000 | -30.3% | 54,874 | -29.8% | 0.00% | -33.3% |
| Q3 2021 | $10,851,000 | +141.9% | 78,116 | +69.1% | 0.01% | +100.0% |
| Q2 2021 | $4,485,000 | +264.0% | 46,203 | +156.2% | 0.00% | +200.0% |
| Q1 2021 | $1,232,000 | -51.4% | 18,032 | -39.1% | 0.00% | -50.0% |
| Q4 2020 | $2,536,000 | +46.4% | 29,591 | +11.1% | 0.00% | +100.0% |
| Q3 2020 | $1,732,000 | -18.9% | 26,643 | -8.8% | 0.00% | -50.0% |
| Q2 2020 | $2,135,000 | +320.3% | 29,205 | +95.8% | 0.00% | – |
| Q1 2020 | $508,000 | -36.3% | 14,918 | +1.9% | 0.00% | -100.0% |
| Q4 2019 | $797,000 | +139.3% | 14,634 | +83.5% | 0.00% | – |
| Q3 2019 | $333,000 | -71.2% | 7,977 | -69.8% | 0.00% | -100.0% |
| Q2 2019 | $1,155,000 | -3.5% | 26,379 | +13.4% | 0.00% | 0.0% |
| Q1 2019 | $1,197,000 | +79.7% | 23,263 | +30.6% | 0.00% | 0.0% |
| Q3 2017 | $666,000 | – | 17,817 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 1,111,111 | $107,867,000 | 52.60% |
| Knoll Capital Management, LLC | 856,844 | $83,182,000 | 43.44% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,082,555 | $202,174,000 | 27.86% |
| ARS Investment Partners, LLC | 558,286 | $54,198,000 | 5.52% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $17,113,000 | 4.52% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 401,006 | $38,930,000 | 4.51% |
| Eventide Asset Management | 1,990,797 | $193,267,000 | 2.60% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 56,626 | $5,497,000 | 2.45% |
| Avidity Partners Management LP | 882,500 | $85,673,000 | 2.32% |
| Nicholas Investment Partners, LP | 363,708 | $35,309,000 | 2.22% |